Open tender · Germany · Contract notice
Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)
Techniker Krankenkasse in Germany is inviting bids for “Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)”. Bids close on 28 February 2027. To qualify, bidders need at least one similar completed work and GST registration.
The work
The tender is for a pharmaceutical entrepreneur to enter into a national discount contract for the drug combination Lamivudin/Abacavir/Dolutegravir with the Techniker Krankenkasse (TK).
- Must be a pharmaceutical entrepreneur as defined by § 4 Abs. 18 AMG.
- Must have a valid marketing authorization (Zulassung) for the specific drug combination in the EU or EEA.
- Must be based in the EU or EEA.
Key facts
- Contract period
- Maximum 24 months from 01.03.2025.
- Evaluation
- The tender is a 'one-size-fits-all' contract where all suitable partners are accepted based on meeting the eligibility criteria.
What it takes to qualify
Worth a closer look
- The tender document is an excerpt and does not contain information on the submission mode, envelope structure, or key dates like the submission deadline.
Experience
- At least 1 similar work — No similar works specified.
- No specific experience required.
Certifications and registrations
Valid marketing authorization (Zulassung)For the specific drug combination Lamivudin/Abacavir/Dolutegravir.
GST registrationThe tender is for a German entity (TK) and does not require an Indian GST registration.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Eigenerklärung zur Zulassung und zum Unternehmen (Anlage 4 zum Vertrag)Self-declaration of being a pharmaceutical entrepreneur and having a valid marketing authorization.
- Eigenerklärung zur ZuverlässigkeitSelf-declaration of no legal convictions for exclusion or events in the last 3 years.